Literature DB >> 9783903

Action of 1,25(OH)2D3 on the cell cycle genes, cyclin D1, p21 and p27 in MCF-7 cells.

L Verlinden1, A Verstuyf, R Convents, S Marcelis, M Van Camp, R Bouillon.   

Abstract

1,25(OH)2D3 is a known growth inhibitor and differentiation inducer of several cancer cell lines. To establish the molecular mechanism of 1,25(OH)2D3 as an antiproliferating agent, its effect on proliferation and gene regulation was studied in human breast cancer MCF-7 cells. 1,25(OH)2D3 inhibited cell proliferation dose dependently through G1 arrest. Cyclin D1 transcription levels decreased rapidly in 1,25(OH)2D3-treated cells while protein levels only decreased after 72 h of treatment. Transcription levels of p21 and p27 were upregulated with chronologically consistent changes in cell cycle distribution. Experiments with TGF-beta neutralising antibodies revealed that the largest effect of 1,25(OH)2D3 on cell proliferation is likely due to a TGF-beta independent mechanism of action. The cell cycle regulatory genes, cyclin D1 and p27, are probably involved herein as their expression was not affected by the presence of neutralising antibodies. However, upregulation of p21 was completely abrogated. Therefore, the TGF-beta signalling pathway is thought to be responsible for p21 upregulation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9783903     DOI: 10.1016/s0303-7207(98)00117-8

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  40 in total

1.  EB1089, a vitamin D receptor agonist, reduces proliferation and decreases tumor growth rate in a mouse model of hormone-induced mammary cancer.

Authors:  Erin L Milliken; Xiaoxue Zhang; Chris Flask; Jeffrey L Duerk; Paul N MacDonald; Ruth A Keri
Journal:  Cancer Lett       Date:  2005-08-22       Impact factor: 8.679

2.  The potential role of vitamin D in the progression of benign and malignant melanocytic neoplasms.

Authors:  Joel Pinczewski; Andrzej Slominski
Journal:  Exp Dermatol       Date:  2010-10       Impact factor: 3.960

Review 3.  Differentiation therapy of leukemia: 3 decades of development.

Authors:  Daniel Nowak; Daphne Stewart; H Phillip Koeffler
Journal:  Blood       Date:  2009-02-12       Impact factor: 22.113

4.  Restoration of the anti-proliferative and anti-migratory effects of 1,25-dihydroxyvitamin D by silibinin in vitamin D-resistant colon cancer cells.

Authors:  Vandanajay Bhatia; Miriam Falzon
Journal:  Cancer Lett       Date:  2015-04-03       Impact factor: 8.679

5.  How I treat vitamin d deficiency.

Authors:  Qamar J Khan; Carol J Fabian
Journal:  J Oncol Pract       Date:  2010-03       Impact factor: 3.840

Review 6.  The roles of UVB and vitamin D in reducing risk of cancer incidence and mortality: A review of the epidemiology, clinical trials, and mechanisms.

Authors:  Meis Moukayed; William B Grant
Journal:  Rev Endocr Metab Disord       Date:  2017-06       Impact factor: 6.514

7.  Effect of dietary vitamin D and calcium on the growth of androgen-insensitive human prostate tumor in a murine model.

Authors:  Rahul Ray; Mara Banks; Hilal Abuzahra; Vikram J Eddy; Kelly S Persons; M Scott Lucia; James R Lambert; Michael F Holick
Journal:  Anticancer Res       Date:  2012-03       Impact factor: 2.480

8.  Dexamethasone enhances 1alpha,25-dihydroxyvitamin D3 effects by increasing vitamin D receptor transcription.

Authors:  Alejandro A Hidalgo; Kristin K Deeb; J Wesley Pike; Candace S Johnson; Donald L Trump
Journal:  J Biol Chem       Date:  2011-08-25       Impact factor: 5.157

9.  Vitamin D-dependent suppression of endothelin-induced vascular smooth muscle cell proliferation through inhibition of CDK2 activity.

Authors:  Songcang Chen; Christopher S Law; David G Gardner
Journal:  J Steroid Biochem Mol Biol       Date:  2009-12-02       Impact factor: 4.292

Review 10.  Vitamin D and human health: lessons from vitamin D receptor null mice.

Authors:  Roger Bouillon; Geert Carmeliet; Lieve Verlinden; Evelyne van Etten; Annemieke Verstuyf; Hilary F Luderer; Liesbet Lieben; Chantal Mathieu; Marie Demay
Journal:  Endocr Rev       Date:  2008-08-11       Impact factor: 19.871

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.